MiniMed Group (NASDAQ:MMED) Upgraded by Benchmark to Strong-Buy Rating

Benchmark upgraded shares of MiniMed Group (NASDAQ:MMED) to a strong-buy rating in a report issued on Monday morning,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Citigroup initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $23.00 target price on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $20.00 target price on the stock. Piper Sandler initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “neutral” rating and a $16.00 target price on the stock. Evercore initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They set an “outperform” rating and a $20.00 target price on the stock. Finally, BTIG Research initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $25.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.25.

MiniMed Group Stock Up 6.5%

Shares of MMED stock opened at $11.89 on Monday. MiniMed Group has a 1-year low of $11.10 and a 1-year high of $20.48. The company has a 50-day moving average of $14.42.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.